Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved..
BACKGROUND: ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab and lapatinib or trastuzumab and pertuzumab. We present long-term clinical results of trastuzumab and lapatinib (HERACLES-A trial) at 6.7 years (82 months) follow-up and focus on central nervous system (CNS) recurrences.
PATIENTS AND METHODS: Patients had histologically confirmed KRAS exon 2 (codons 12 and 13) wild-type and HER2-positive mCRC. HER2 positivity was assessed by immunohistochemistry and in situ hybridization HERACLES diagnostic criteria. Patients were treated with intravenous trastuzumab 4 mg/kg loading dose, then 2 mg/kg once per week, and oral lapatinib 1000 mg per day until disease progression or toxicity. Patients who presented with symptoms or signs of CNS disease received brain computed tomography scan or magnetic resonance imaging.
RESULTS: A total of 35 patients received trastuzumab and lapatinib and 32 were evaluable for response. One patient (3%) achieved complete response (CR), 8 (25%) partial response, and 13 (41%) stable disease. Therefore, response rate was 28%. Median progression-free survival was 4.7 months (95% confidence interval [CI] 3.7-6.1). Median overall survival was 10.0 months (95% CI 7.9-15.8). One patient achieved sustained CR still maintained at 7 years of follow-up. Progression in the central nervous system (CNS) occurred in 6 (19%) of 32 patients.
CONCLUSIONS: Long-term (6.7 years) follow-up analysis of HERACLES-A supports using of trastuzumab and lapatinib as treatment reference for KRAS wild-type, chemorefractory HER2-positive mCRC. In this subset of patients, prolongation of survival is accompanied by CNS recurrences that will require diagnostic and therapeutic attention in future studies. Clinicaltrials. Gov identifier: NCT 03225937.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Clinical colorectal cancer - 19(2020), 4 vom: 30. Dez., Seite 256-262.e2 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tosi, Federica [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.11.2021 Date Revised 22.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clcc.2020.06.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314919791 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314919791 | ||
| 003 | DE-627 | ||
| 005 | 20231225153800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clcc.2020.06.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1049.xml |
| 035 | |a (DE-627)NLM314919791 | ||
| 035 | |a (NLM)32919890 | ||
| 035 | |a (PII)S1533-0028(20)30094-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tosi, Federica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.11.2021 | ||
| 500 | |a Date Revised 22.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab and lapatinib or trastuzumab and pertuzumab. We present long-term clinical results of trastuzumab and lapatinib (HERACLES-A trial) at 6.7 years (82 months) follow-up and focus on central nervous system (CNS) recurrences | ||
| 520 | |a PATIENTS AND METHODS: Patients had histologically confirmed KRAS exon 2 (codons 12 and 13) wild-type and HER2-positive mCRC. HER2 positivity was assessed by immunohistochemistry and in situ hybridization HERACLES diagnostic criteria. Patients were treated with intravenous trastuzumab 4 mg/kg loading dose, then 2 mg/kg once per week, and oral lapatinib 1000 mg per day until disease progression or toxicity. Patients who presented with symptoms or signs of CNS disease received brain computed tomography scan or magnetic resonance imaging | ||
| 520 | |a RESULTS: A total of 35 patients received trastuzumab and lapatinib and 32 were evaluable for response. One patient (3%) achieved complete response (CR), 8 (25%) partial response, and 13 (41%) stable disease. Therefore, response rate was 28%. Median progression-free survival was 4.7 months (95% confidence interval [CI] 3.7-6.1). Median overall survival was 10.0 months (95% CI 7.9-15.8). One patient achieved sustained CR still maintained at 7 years of follow-up. Progression in the central nervous system (CNS) occurred in 6 (19%) of 32 patients | ||
| 520 | |a CONCLUSIONS: Long-term (6.7 years) follow-up analysis of HERACLES-A supports using of trastuzumab and lapatinib as treatment reference for KRAS wild-type, chemorefractory HER2-positive mCRC. In this subset of patients, prolongation of survival is accompanied by CNS recurrences that will require diagnostic and therapeutic attention in future studies. Clinicaltrials. Gov identifier: NCT 03225937 | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CNS metastases | |
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a HER2 | |
| 650 | 4 | |a Lapatinib | |
| 650 | 4 | |a Trastuzumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a KRAS protein, human |2 NLM | |
| 650 | 7 | |a Lapatinib |2 NLM | |
| 650 | 7 | |a 0VUA21238F |2 NLM | |
| 650 | 7 | |a ERBB2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a pertuzumab |2 NLM | |
| 650 | 7 | |a K16AIQ8CTM |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 700 | 1 | |a Sartore-Bianchi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Lonardi, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Amatu, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Leone, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Ghezzi, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Martino, Cosimo |e verfasserin |4 aut | |
| 700 | 1 | |a Bencardino, Katia |e verfasserin |4 aut | |
| 700 | 1 | |a Bonazzina, Erica |e verfasserin |4 aut | |
| 700 | 1 | |a Bergamo, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Fenocchio, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Martinelli, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Troiani, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Siravegna, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Mauri, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Torri, Valter |e verfasserin |4 aut | |
| 700 | 1 | |a Marrapese, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Valtorta, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Cassingena, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cappello, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Bonoldi, Emanuela |e verfasserin |4 aut | |
| 700 | 1 | |a Vanzulli, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Regge, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Ciardiello, Fortunato |e verfasserin |4 aut | |
| 700 | 1 | |a Zagonel, Vittorina |e verfasserin |4 aut | |
| 700 | 1 | |a Bardelli, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Trusolino, Livio |e verfasserin |4 aut | |
| 700 | 1 | |a Marsoni, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Siena, Salvatore |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical colorectal cancer |d 2000 |g 19(2020), 4 vom: 30. Dez., Seite 256-262.e2 |w (DE-627)NLM122314204 |x 1938-0674 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2020 |g number:4 |g day:30 |g month:12 |g pages:256-262.e2 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clcc.2020.06.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2020 |e 4 |b 30 |c 12 |h 256-262.e2 | ||